Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Summary

This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.

Conditions

• Acute Myocardial Infarction

Interventions

DRUG

Empagliflozin 10 mg

The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.

DRUG

Placebo Oral Tablet

The subject will receive Placebo orally once daily for 26 weeks.

Sponsors & Collaborators

• United Arab Emirates University

  collaborator OTHER

• Medical University of Vienna

  collaborator OTHER

• Landeskrankenhaus Feldkirch

  collaborator OTHER

• Paracelsus Medical University

  collaborator OTHER

• Hospital Rudolfstiftung

  collaborator OTHER

• Klinikum Klagenfurt am Wörthersee

  collaborator OTHER

• Barmherzige Brüder Eisenstadt

  collaborator OTHER

• Cardinal Schwarzenberg Hospital

  collaborator OTHER

• Johannes Kepler University of Linz

  collaborator OTHER

• Landesklinikum Sankt Polten

  collaborator OTHER

• Landeskrankenhaus II Graz West

  collaborator OTHER

• Medical University of Graz

  lead OTHER

Principal Investigators

• Harald Sourij, Assoc.-Prof. · Medical University of Graz

• Dirk von Lewinski, Assoc.-Prof. · Medical University of Graz

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-05-11

Primary Completion

2022-05-03

Completion

2022-05-17

Countries

• Austria

Study Locations